Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.48 |
| ▸ | INSR | P06213 | 7/20 | 0.48 |
| ▸ | SYK | P43405 | 3/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576521 | 0.90 | TBK1 (0.49) | KDRAURKBTBK1SYKPTK2 | |
| SCHEMBL578664 | 0.86 | AURKB (0.54) | KDRAURKBALKINSRSYK | |
| SCHEMBL4281514 | 0.86 | AURKB (0.54) | KDRAURKBALKINSRSYK | |
| SCHEMBL578750 | 0.81 | SYK (0.50) | KDRAURKBALKINSRSYK | |
| SCHEMBL578749 | 0.81 | SYK (0.50) | KDRAURKBALKINSRSYK | |
| SCHEMBL13313534 | 0.81 | TBK1 (0.50) | KDRAURKBTBK1SYKPTK2 | |
| SCHEMBL3769576 | 0.80 | AURKB (0.78) | KDRAURKB | |
| SCHEMBL3772297 | 0.80 | AURKB (0.78) | KDRAURKB | |
| SCHEMBL13313554 | 0.79 | KDR (0.49) | KDRAURKBALKINSRSYK | |
| SCHEMBL4198572 | 0.78 | PTK2 (0.57) | KDRAURKBTBK1ALKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| WO-2008077885-A2 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144706-A1 | Compounds | MKI67, CCNA1, CCNT1 | KDR 2478/4885AURKB 1956/4885TBK1 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.